Alzinova AB (SE:ALZ)

:ALZ

ALZ

Alzinova AB

RESEARCH TOOLSreports

Alzinova AB (ALZ) Price & Analysis

2 Followers

ALZ Stock Chart & Stats

kr0.82

-kr0.14(-4.96%)

At close: Mar 06 4:00 PM EST

kr0.82

-kr0.14(-4.96%)

Day’s Range― - ―

52-Week Rangekr0.57 - kr2.28

Previous CloseN/A

Volume98.89K

Average Volume (3M)655.64K

Market Cap

kr92.64M

Enterprise Valuekr64.28M

Total Cash (Recent Filing)kr319.00K

Total Debt (Recent Filing)kr800.00K

Price to Earnings (P/E)―

Beta0.14

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding154,398,900

10 Day Avg. Volume664,473

30 Day Avg. Volume655,642

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)0.68

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.63

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthVery low debt and minimal leverage provide durable financial flexibility for a pre-commercial biotech. This reduces insolvency risk, gives time to progress clinical programs or negotiate deals, and supports funding runway via equity or strategic partnerships over months.

Focused Disease‑modifying PipelineA focused lead program targeting a validated Alzheimer’s mechanism aligns with a large, persistent unmet medical need. Maintaining a single, differentiated asset (plus related antibodies) concentrates resources and can accelerate meaningful clinical milestones or partnering interest over the medium term.

Partnering / Out‑licensing Business ModelA partnership-led commercialization strategy is durable for small biotechs: it enables risk sharing, upfront and milestone payments, and access to commercialization capabilities without needing a large sales structure, preserving capital and scaling options as programs advance.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow creates a structural funding need. Over months this necessitates external financing or partner funding, increasing dilution risk and potentially forcing suboptimal deal terms or development delays if markets tighten.

Near‑zero Revenue And Widening LossesA collapsing top line and expanding losses indicate the company cannot self-fund operations. Structurally, this undermines sustainable operations absent new financing or successful licensing, raising execution risk for clinical programs and dependency on external capital.

Very Small Operational ScaleA tiny headcount signals limited internal capacity to run multiple complex clinical or regulatory tasks. Reliance on external CROs and partners increases operational and oversight risk, potentially slowing timelines and increasing costs compared with better-staffed peers.

ALZ FAQ

What was Alzinova AB’s price range in the past 12 months?

Alzinova AB lowest stock price was kr0.57 and its highest was kr2.28 in the past 12 months.

What is Alzinova AB’s market cap?

Alzinova AB’s market cap is kr92.64M.

When is Alzinova AB’s upcoming earnings report date?

Alzinova AB’s upcoming earnings report date is May 20, 2026 which is in 45 days.

How were Alzinova AB’s earnings last quarter?

Alzinova AB released its earnings results on Mar 25, 2026. The company reported -kr0.055 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.055.

Is Alzinova AB overvalued?

According to Wall Street analysts Alzinova AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alzinova AB pay dividends?

Alzinova AB does not currently pay dividends.

What is Alzinova AB’s EPS estimate?

Alzinova AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alzinova AB have?

Alzinova AB has 154,398,900 shares outstanding.

What happened to Alzinova AB’s price movement after its last earnings report?

Alzinova AB reported an EPS of -kr0.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.125%.

Which hedge fund is a major shareholder of Alzinova AB?

Currently, no hedge funds are holding shares in SE:ALZ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alzinova AB

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.